☆ 4.6 Article

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

PHARMACEUTICALS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

Liran Holtzman et al.

Summary: This study retrospectively compared the efficacy of first-line pembrolizumab alone and pembrolizumab in combination with platinum-based chemotherapy in patients with PD-L1 TPS >= 50% non-small cell lung cancer. The results showed no difference in overall survival between the two treatment options. A predictive score incorporating age, sex, smoking, histology, and dNLR was developed to predict patient survival with pembrolizumab alone and pembrolizumab in combination with chemotherapy.

CLINICAL LUNG CANCER (2022)

添加到收藏夹

Review Oncology

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

Aaron C. Tan et al.

Summary: The therapeutic landscape of non-small-cell lung cancer is undergoing significant changes with the shift from histology-based classification to molecularly defined subsets. Targeted therapies for specific driver mutations such as EGFR, ALK, and ROS1 have shown promising results, and there is a growing list of approved therapies for other mutations. The importance of diagnostic molecular testing, optimal sequencing of therapies, application of targeted therapies in early-stage disease, and the impact of genomic mutations on targeted therapy efficacy are important areas of research.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

First-Line Immunotherapy for Non-Small-Cell Lung Cancer

Martin Reck et al.

Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Hallmarks of Cancer: New Dimensions

Douglas Hanahan

Summary: The concept of the hallmarks of cancer is a tool for simplifying the complexity of cancer phenotypes and genotypes into basic principles. This article proposes phenotypic plasticity and disrupted differentiation as distinct hallmark capabilities, and discusses nonmutational epigenetic reprogramming and polymorphic microbiomes as enabling characteristics. Additionally, the importance of senescent cells in the tumor microenvironment is highlighted. The integrative concept of the hallmarks of cancer helps in understanding the mechanisms of cancer development and applying that knowledge to cancer medicine.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial

Hiromi Matsumoto et al.

Summary: This study compared the efficacy of pembrolizumab alone and in combination with chemotherapy in NSCLC patients with high PD-L1 expression. Results showed no significant differences in progression-free survival, overall survival, and response rate between the two groups, but patients with metastases to specific sites may benefit more from monotherapy.

THORACIC CANCER (2022)

添加到收藏夹

Article Oncology

Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

Howard Jack West et al.

Summary: Atezolizumab combined with bevacizumab and chemotherapy is an effective first-line treatment in metastatic non-squamous non-small cell lung cancer subgroups with mKRAS and co-occurring STK11 and/or KEAP1 or TP53 mutations and/or high PD-L1 expression. Mutation of STK11 and/or KEAP1 can serve as poor prognostic indicators.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Oncology

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Hiroshi Takumida et al.

Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy and monotherapy for non-small cell lung cancer with high expression of PD-L1. Both treatment strategies showed similar effectiveness in time to treatment failure, making them valid options for NSCLC patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti et al.

Summary: STK11 and KEAP1 mutations have a negative impact on the efficacy of immunotherapy in lung adenocarcinoma, but this effect is only observed in KRAS-positive tumors. Tumors with concurrent KRAS/STK11 and KRAS/KEAP1 mutations exhibit distinct immune characteristics.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non-small cell lung cancer

Xiaojuan Lu et al.

Summary: This study selects platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for non-small cell lung cancer (NSCLC) patients, and finds that NLR is an independent prognostic factor.

ONCOLOGY LETTERS (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Cristina Valero et al.

Summary: The study demonstrates the association of higher neutrophil-to-lymphocyte ratio (NLR) with poorer survival outcomes and lower rates of response across multiple cancer types treated with immune checkpoint inhibitors (ICI). Combining NLR with tumor mutational burden (TMB) significantly increases the probability of benefit from ICI, with the low NLR/high TMB group showing the highest likelihood of benefit. These findings highlight the potential of NLR as a cost-effective and widely accessible biomarker for predicting response to ICI therapy.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer

Taisuke Isono et al.

Summary: A retrospective study compared pembrolizumab plus chemotherapy with pembrolizumab monotherapy in non-small cell lung cancer patients, showing no significant difference in ORR and OS between the two groups. The combination therapy group had more adverse events and a higher rate of treatment discontinuation compared to the monotherapy group.

THORACIC CANCER (2021)

添加到收藏夹

Article Oncology

Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer

Joao Alessi et al.

Summary: In patients with NSCLC and PD-L1 TPS >= 50%, a low dNLR value is associated with a distinct immune tumor microenvironment and more favorable clinical outcomes to first-line pembrolizumab, including higher objective response rate, longer progression-free survival, and longer overall survival.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab

Amparo Sanchez-Gastaldo et al.

Summary: Low baseline NLR, MLR, and PLR are significantly associated with better PFS, while low baseline NLR and PLR are associated with better OS. Additionally, the RBB score identified three subgroups of patients, with low scores being associated with improved survival outcomes and response to therapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

Elizabeth Dudnik et al.

Summary: The study compared the efficacy of pembrolizumab (P) and a combination of pembrolizumab with platinum-based chemotherapy (PCT) as first-line treatments, showing similar outcomes in patients with EGFR/ALK/ROS1 wild-type PD-L1 TPS >= 50% non-small cell lung cancer. While differences may exist in certain specific patient subgroups, overall, there were no significant differences in long-term outcomes between the two treatment strategies.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Critical Care Medicine

Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

Willemijn S M E Theelen et al.

Lancet Respiratory Medicine (2020)

添加到收藏夹

Article Oncology

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

James Welsh et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort

Simon Papillon-Cavanagh et al.

ESMO OPEN (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S. K. Mok et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial

Willemijn S. M. E. Theelen et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer

L. Paz-Ares et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Oncology

Using immunotherapy to boost the abscopal effect

Wilfred Ngwa et al.

NATURE REVIEWS CANCER (2018)

添加到收藏夹

Article Oncology

Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer

Xiaomei Gong et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Stefan Diem et al.

LUNG CANCER (2017)

添加到收藏夹

Article Oncology

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

Simon J. Dovedi et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Martin Reck et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor et al.

NATURE (2015)

添加到收藏夹

Article Medicine, Research & Experimental

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice

Liufu Deng et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria

Temel Tirkes et al.

RADIOGRAPHICS (2013)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.